ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2555

Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction
Abstract Number: 0720

Cognitive Function and Its Associated Factors in Polymyalgia Rheumatica
Abstract Number: 2449

Cognitive Functioning Among Individuals with Systemic Lupus Erythematosus: A Population-Based Study
Abstract Number: 1234

Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity
Abstract Number: 2105

Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases
Abstract Number: 1183

CoLchicine for Treatment of OsteoArthritis of the Knee—Updated Data from a Double-blind, Placebo-controlled Trial
Abstract Number: 1977

Combined Datasets for CNTX-4975 Osteoarthritis Knee Pain (OAKP) Phase 3 Trials (OAKP 301 and 304) to Assess Overall Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP)
Abstract Number: 1593

Combining Single-cell RNA Sequencing and Population-based Studies Reveals Hand Osteoarthritis-associated Chondrocyte Subpopulations and Pathways
Abstract Number: 1564

Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Suspected Behçet’s Disease
Abstract Number: 2171

Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?
Abstract Number: 0249

Comorbidities of Gout: Results from the Korean National Health and Nutrition Examination Survey
Abstract Number: 1394

Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study
Abstract Number: 1895

Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies
Abstract Number: 2079

Comparative Analysis of Teledidactic and On-Campus Training in Musculoskeletal Ultrasound – the TELMUS Study
Abstract Number: 0338

Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis: Data from COVAD Patient-reported E-survey

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].